Kathryn-Ann
Stamm

On October 29, 2026, ADT Inc. (“ADT”), a leading provider of security, interactive and smart home solutions serving residential and small business customers in the U.S., and Thrive Holdings, a permanent capital holding company focused on investing in established businesses and advancing their capabilities through technology, announced a definitive agreement under which Thrive Holdings will acquire ADT in an all‑cash transaction. The agreement values ADT at approximately $7.6 billion in equity value and $15.3 billion in enterprise value. Under the terms of the agreement, which ADT’s Board of Directors unanimously approved, ADT stockholders will receive $10.00 per share in cash upon completion. Following completion, ADT will become privately held and its common stock will cease trading on the New York Stock Exchange. Cravath is representing ADT in connection with the transaction.

On October 20, 2026, Alcon, a global leader in eye care, announced it has acquired Neurotech Pharmaceuticals, Inc. (“Neurotech”), a company focused on developing innovative cell therapies for chronic and neurodegenerative eye diseases, for $550 million. Alcon may be required to make additional contingent payments, including upon the achievement of commercial milestones. This acquisition expands Alcon's retina portfolio with ENCELTO™, the first and only U.S. FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2 (“MacTel”), a rare, progressive retinal disease that leads to irreversible central vision loss that has historically had no approved treatment options. Cravath represented Neurotech in connection with the transaction.

On August 6, 2026, Harrow, a leading provider of ophthalmic disease management solutions in North America, announced that it has entered into a definitive agreement to acquire TYRVAYA® (varenicline solution) nasal spray 0.03 mg from Viatris Inc. (“Viatris”), a global healthcare company. TYRVAYA is a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease (DED) and is currently approved in the U.S., China, and Taiwan, with marketing authorization applications pending in other countries. Under the terms of the agreement, Harrow will pay $30 million in cash at closing and up to $70 million in contingent milestone payments tied to TYRVAYA's net sales, for a potential total consideration of up to $100 million. Cravath is representing Viatris in connection with the transaction.

On March 31, 2026, Biogen Inc. and Apellis Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which Biogen has agreed to acquire all outstanding shares of Apellis for $41.00 per share in cash at closing, or approximately $5.6 billion. Apellis stockholders will also receive a nontransferable CVR for each Apellis share held, entitling the holder to receive two payments of $2 per share each, contingent on certain annual global net sales thresholds being met for SYFOVRE®. Cravath is representing Biogen in connection with the transaction.

On February 27, 2026, Paramount Skydance Corporation (“Paramount”) and Warner Bros. Discovery, Inc. ("WBD") announced they have entered into a definitive merger agreement under which Paramount will acquire WBD. Under the terms of the agreement, Paramount will pay $31.00 per share in cash for all outstanding shares of WBD. The transaction values WBD at an enterprise value of $110 billion, and has been unanimously approved by the Boards of Directors of both companies. Cravath is representing Paramount in connection with the transaction.

On October 26, 2026, Intellectual Asset Management (IAM) and World Trademark Review (WTR) published an article by Cravath partners David J. Kappos and Ryan J. Wichtowski and of counsel Kathryn‑Ann Stamm entitled “Rethinking IP Protection Strategies in the Age of AI.” The article examines how developments in AI are challenging traditional approaches to IP protection and recommends that companies combine IP rights with technical architecture, contractual discipline and relationship management to build the most resilient protection strategies.

On July 6, 2026, World Intellectual Property Review (“WIPR”) included Cravath of counsel Kathryn‑Ann Stamm as part of its 2026 “Influential Women in IP” list. The list, selected through an in‑depth process that combines nominations, independent research and assessments by the WIPR editorial team, celebrates the women “whose expertise, leadership and achievements are shaping the future of intellectual property across the globe.”

On June 19, 2026, Intellectual Asset Management ("IAM") published an article written by Cravath partner David J. Kappos, of counsel Kathryn-Ann Stamm and associate Sarah R. Brathwaite entitled "The Clock Is Already Ticking: A Practical Guide to Turning Your Patent into a Product." The article provides inventors with a roadmap for turning their patent rights promptly into commercial value, emphasizing the importance of early commercialization planning and thoughtful structuring of deal pathways and terms.

On May 28, 2026, Cravath of counsel Kathryn-Ann Stamm was honored at The Legal Benchmarking Group’s Women in Business Law Americas Awards in New York, where she was recognized as the 2026 “North America Intellectual Property Rising Star.” Now in its 15th year, the Awards program recognizes leading legal practitioners who are breaking new ground in their areas of expertise.

Cravath of counsel Kathryn‑Ann Stamm participated in the African Women Entrepreneurship Cooperative’s 2026 General Assembly, themed “Legacy,” which was held from April 15‑17 in Lusaka, Zambia. Kathryn‑Ann led a multi‑session learning lab entitled “Protecting What You Build: Turning Your Brand, Ideas & Knowledge Into Legacy Assets,” which guided entrepreneurs through how to identify, strengthen, and legally protect the intellectual property assets already embedded in their businesses, from brand names and creative content to trade secrets, customer data and online presence. Through hands‑on exercises and real‑world case studies, the learning lab equipped attendees with a practical toolkit, including strategies for trademark registration, copyright documentation, confidentiality agreements, and the responsible use of AI, empowering them to turn their brands, ideas, and knowledge into durable legacy assets. Kathryn‑Ann also facilitated a business dialogue entitled “If You Stepped Away Tomorrow: Getting What’s in Your Head Into Your Business,” which challenged participants to evaluate whether their critical business assets, such as their name and branding, recipes and formulas, operational processes, customer knowledge, and internet properties, are properly documented, organized and owned by the business itself rather than residing solely with the founder.